Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, evaluator-blinded, comparative study to evaluate the efficacy and safety of different injection volumes of botulinum toxin type A, Azzalure, in the glabellar lines

Next Previous
Trial Profile

A randomized, evaluator-blinded, comparative study to evaluate the efficacy and safety of different injection volumes of botulinum toxin type A, Azzalure, in the glabellar lines

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Galderma Research & Development; Q-Med

Most Recent Events

  • 12 Aug 2015 Status changed from recruiting to completed as per ClinicalTrials.gov record.
  • 04 Jun 2014 According to the ClinicalTrials.gov record, planned end date changed from 17 Jan 2015 to 1 Nov 2014.
  • 04 Jun 2014 New source identified and integrated (ClinicalTrials.gov record: NCT02108158)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top